< 回列表
楊政達 Cheng-Ta Yang
- Superintendent, Taoyuan Chang Gung Memorial Hospital
Just-Right Therapy: Building Durable Control in Challenging NSCLC
| 角色 | 座長 |
| 日期時間 | 05/02 12:00 - 13:00 |
| 地點 | 701B |
台灣肺癌學會第九屆第三次會員大會
| 角色 | 座長 |
| 日期時間 | 05/02 13:30 - 14:00 |
| 地點 | 701B |
Opening
| 角色 | 座長 |
| 日期時間 | 05/02 14:00 - 14:10 |
| 地點 | 701B |
學歷 / 訓練
1989, Medical Department, Kaoshiung Medical College, Kaoshiung City, Taiwan
1989, Internship at Chang Gung Memorial Hospital, Taipei
專業與研究經歷
2015 - Present, Professor, Department of Respiratory Therapy, College of Medicine, Chang Gung University
2014 - Present, Professor, Department of Thoracic Medicine, Chang Gung Memorial Hospitals
2009 - Present, Attending Physician, Department of Thoracic Medicine, Chang Gung Memorial Hospital, Taoyuan, Taipei and Linkou
2016 - 2015, Associate Professor, Department of Respiratory Care, College of Medicine, Chang Gung University
2002 - 2006, Assistant Professor, Department of Respiratory Care, College of Medicine, Chang Gung University
2001 - 2009, Attending Physician, Division of Pulmonary and Critical Care Medicine, Chiayi Chang Gung Memorial Hospital
重要出版品
- Gee-Chen Chang*, Chao-Hua Chiu*, Chong-Jen Yu*, Yeun-Chung Chang, Ya-Hsuan Chang, Kuo-Hsuan Hsu, Yu-Chung Wu, Chih-Yi Chen, Hsian-He Hsu, Ming-Ting Wu, Cheng-Ta Yang, Inn-Wen Chong, Yu-Ching Lin, Te-Chun Hsia, Meng-Chih Lin, Wu-Chou Su, Chih-Bin Lin, Kang-Yun Lee, Yu-Feng Wei, Gong-Yau Lan, Wing P Chan, Kao-Lun Wang, Mei-Han Wu, Hao-Hung Tsai, Chih-Feng Chian, Ruay-Sheng Lai, Jin-Yuan Shih, Chi-Liang Wang, Jui-Sheng Hsu, Kun-Chieh Chen, Chun-Ku Chen, Jiun-Yi Hsia, Chung-Kan Peng, En-Kuei Tang, Chia-Lin Hsu, Teh-Ying Chou, Wei-Chih Shen, Ying-Huang Tsai, Chun-Ming Tsai, Yuh-Min Chen, Yu-Chin Lee, Hsuan-Yu Chen, Sung-Liang Yu, Chien-Jen Chen, Yung-Liang Wan, Chao Agnes Hsiung, Pan-Chyr Yang, on behalf of the TALENT Investigators. Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study. Lancet Respiratory Medicine 2023 Nov 29:S2213-2600(23)00338-7. doi: 10.1016/S2213-2600(23)00338-7. Online ahead of print.
- Jia‑Shiuan Ju, Allen Chung‑Cheng Huang, Pi‑Hung Tung, Chi‑Hsien Huang, Tzu‑Hsuan Chiu, Chin‑Chou Wang, How‑Wen Ko, Fu‑Tsai Chung, Ping‑Chih Hsu, Yueh‑Fu Fang, Yi‑Ke Guo, Chih‑Hsi Scott Ku* & Cheng‑Ta Yang. Brain metastasis, EGFR mutation subtype and generation of EGFR‑TKI jointly influence the treatment outcome of patient with EGFR‑mutant NSCLC. Scientific Reports 2023 Nov 21;13(1):20323. doi: 10.1038/s41598-023-45815-8.
- Edward B. Garon*, Byoung Chul Cho, Alexander Luft, Jorge Alatorre-Alexander, Sarayut Lucien Geater, Sang-We Kim, Grygorii Ursol, Maen Hussein, Farah Louise Lim, Cheng-Ta Yang, Luiz Henrique Araujo, Haruhiro Saito, Niels Reinmuth, Nenad Medic, Helen Mann, Xiaojin Shi, Solange Peters, Tony Mok, Melissa Johnson. Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON). Lung Cancer 2023 Dec:186:107422. doi: 10.1016/j.lungcan.2023.107422. Epub 2023 Nov 11.
- Chien-Yu Lin*, Yun-Tse Chou, Po-Lan Su, Chien-Chung Lin, John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, Cheng-Ta Yang, Chiao-En Wu. Generation and validation of a predictive model for estimating survival among patients with EGFR-mutant non-small cell lung cancer. American Journal of Clinical Research 2023 Sep 15;13(9):4208-4221. eCollection 2023.
- Shu-Er Chow, Chia-Chi Hsu, Cheng-Ta Yang and Yaa-Jyuhn J. Meir*. YAP co-localizes with the mitotic spindle and midbody to safeguard mitotic division in lung-cancer cells. The FEBS Journal 2023 Aug 7. doi: 10.1111/febs.16926. Online ahead of print.
- Hye Ryun Kim1 | Shunichi Sugawara, Jong-Seok Lee, Jin-Hyoung Kang, Naoki Inui, Toyoaki Hida, Ki Hyeong Lee, Tatsuya Yoshida, Hiroshi Tanaka, Cheng-Ta Yang, Makoto Nishio, Yuichiro Ohe, Tomohide Tamura, Nobuyuki Yamamoto, Chong-Jen Yu, Hiroaki Akamatsu1, Shigeru Takahashi, Kazuhiko Nakagawa*. First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial. Cancer Medicine 2023 Aug;12(16):17061-17067.